New filler trial aims to restore youthful cheeks
NCT ID NCT07126912
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests a hyaluronic acid filler called Alcarisa for people with moderate to significant mid-face volume loss. Thirty participants aged 30 to 65 will receive a single injection in the cheek area and be followed for 24 weeks. Doctors will assess results using photos and a volume deficit scale, and participants will report their satisfaction.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Alcarisa hyaluronic acid filler
- What this could lead to
- If it works, this could provide a safe, effective option for restoring mid-face volume with a single injection.
- What could go wrong
- This is a small, early-stage study with only 30 participants and no comparison group. Results may not apply to everyone, and risks include allergic reactions or unsatisfactory results.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2025
- Expected to finish
-
Oct 2025
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
30 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Men and women aged 30 to 65 years * Individuals with moderate to significant mid-face volume loss (score 3 to 4) based on changes in MFVDS (in cases of asymmetry between the two sides of the face, the more severe side will be considered) * Ability to comply with visit schedules and study procedures * Signed the informed consent form and agreed to 6-month follow-up Exclusion Criteria: * History of Type I hypersensitivity reactions or anaphylaxis * Known allergy or sensitivity to any components of the filler, lidocaine, or to proteins from the HA-producing microorganisms (Streptococci) * History of hypertrophic or keloid scarring, or bleeding disorders in the injection area * Active inflammatory processes, infections, lesions (malignant or benign), or scars in the injection area * History of streptococcal diseases (such as recurrent sore throat or acute rheumatic fever) in the past 6 months * History of autoimmune/immunodeficiency diseases, or use of immunosuppressive drugs during the 6 months prior to or during the study * History of surgery or trauma in the injection area within the past 6 months * Use of antiplatelet drugs within 72 hours prior to treatment, or anticoagulants within 2 weeks prior to or during treatment * Use of drugs that reduce or inhibit hepatic metabolism (e.g., cimetidine, beta-blockers) due to the presence of lidocaine * Pregnancy, breastfeeding, or plans to become pregnant in the near future during the study * Undergoing or planning to undergo cosmetic treatments in the near future during the study, such as: 1. Botulinum toxin type A injections below the zygomatic arch during the 6 months prior to study entry 2. Previous injections of temporary dermal fillers (e.g., bovine collagen, hyaluronic acid) in the facial area within 1 year prior to study entry 3. Use of calcium hydroxyapatite, poly-L-lactic acid, or permanent fillers (e.g., silicone), or fat injections in the injection area at any time before or during the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Mid face volume deficit are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Center for Research and Training in Skin Disease and Leprocy
RECRUITINGTehran, Tehran Province, 1416613675, Iran
-
Orchid Pharmed, Medical Department
RECRUITINGTehran, Tehran Province, 19947-66411, Iran
More trials for these conditions
Other studies related to the condition(s) this trial covers.